Published in Neuron on February 19, 2014
Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol (2015) 1.75
Opposing effects of Apoe/Apoa1 double deletion on amyloid-β pathology and cognitive performance in APP mice. Brain (2015) 1.43
Immunotherapeutic approaches for Alzheimer's disease. Neuron (2015) 1.13
More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration. Neuron (2014) 1.04
Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). J Biol Chem (2015) 1.04
The low-density lipoprotein receptor-related protein 1 and amyloid-β clearance in Alzheimer's disease. Front Aging Neurosci (2014) 1.01
ATP-binding cassette transporter A1: from metabolism to neurodegeneration. Neurobiol Dis (2014) 0.98
Developing therapeutic vaccines against Alzheimer's disease. Expert Rev Vaccines (2015) 0.90
Cholesterol in brain disease: sometimes determinant and frequently implicated. EMBO Rep (2014) 0.88
Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisense oligonucleotides. EMBO Mol Med (2016) 0.87
APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice. Mol Neurodegener (2015) 0.85
Modeling the Role of the Glymphatic Pathway and Cerebral Blood Vessel Properties in Alzheimer's Disease Pathogenesis. PLoS One (2015) 0.85
The role of APOE in cerebrovascular dysfunction. Acta Neuropathol (2016) 0.84
HDL and cognition in neurodegenerative disorders. Neurobiol Dis (2014) 0.84
Towards understanding the roles of heparan sulfate proteoglycans in Alzheimer's disease. Biomed Res Int (2014) 0.84
Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway. J Biol Chem (2014) 0.83
Autoregulated paracellular clearance of amyloid-β across the blood-brain barrier. Sci Adv (2015) 0.82
Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice. Mol Neurodegener (2015) 0.82
Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer's disease. Sci Transl Med (2016) 0.81
Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer's disease. Acta Neuropathol (2016) 0.81
Aβ Clearance, "hub" of Multiple Deficiencies Leading to Alzheimer Disease. Front Aging Neurosci (2015) 0.81
The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: Two sides of the same coin. Neurobiol Dis (2015) 0.81
Innate Immunity Fights Alzheimer's Disease. Trends Neurosci (2015) 0.81
Apolipoprotein E lipoprotein particles inhibit amyloid-β uptake through cell surface heparan sulphate proteoglycan. Mol Neurodegener (2016) 0.80
Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS). Oncotarget (2015) 0.80
Maximally asymmetric transbilayer distribution of anionic lipids alters the structure and interaction with lipids of an amyloidogenic protein dimer bound to the membrane surface. Chem Phys Lipids (2016) 0.80
The epigenetic dimension of Alzheimer's disease: causal, consequence, or curiosity? Dialogues Clin Neurosci (2014) 0.80
Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer's Disease Phenotypes. PLoS One (2016) 0.79
Alzheimer's Disease: Mechanism and Approach to Cell Therapy. Int J Mol Sci (2015) 0.79
Implications of GABAergic Neurotransmission in Alzheimer's Disease. Front Aging Neurosci (2016) 0.79
Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1. Exp Neurol (2015) 0.79
Apolipoprotein E Inhibits Cerebrovascular Pericyte Mobility through a RhoA Protein-mediated Pathway. J Biol Chem (2015) 0.79
Mechanisms of Aβ Clearance and Degradation by Glial Cells. Front Aging Neurosci (2016) 0.79
Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes. Cell Mol Life Sci (2017) 0.79
Altered Energy Metabolism Pathways in the Posterior Cingulate in Young Adult Apolipoprotein E ɛ4 Carriers. J Alzheimers Dis (2016) 0.78
ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Aβ Secretion. Cell (2017) 0.77
Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months. PLoS One (2015) 0.77
Non-alcoholic fatty liver disease induces signs of Alzheimer's disease (AD) in wild-type mice and accelerates pathological signs of AD in an AD model. J Neuroinflammation (2016) 0.77
Role of LDL cholesterol and endolysosomes in amyloidogenesis and Alzheimer's disease. J Neurol Neurophysiol (2014) 0.77
Study of Exosomes Shed New Light on Physiology of Amyloidogenesis. Cell Mol Neurobiol (2016) 0.76
Altered Cholesterol Intracellular Trafficking and the Development of Pathological Hallmarks of Sporadic AD. J Parkinsons Dis Alzheimers Dis (2015) 0.76
Towards Personalized Intervention for Alzheimer's Disease. Genomics Proteomics Bioinformatics (2016) 0.76
Orexin signaling regulates both the hippocampal clock and the circadian oscillation of Alzheimer's disease-risk genes. Sci Rep (2016) 0.76
Potential Neuroprotective Effects of Adiponectin in Alzheimer's Disease. Int J Mol Sci (2017) 0.75
TREM2-ligand interactions in health and disease. J Mol Biol (2017) 0.75
Islet adaptation to obesity and insulin resistance in WNIN/GR-Ob rats. Islets (2014) 0.75
Association of smoking and alcohol drinking with dementia risk among elderly men in China. Curr Alzheimer Res (2014) 0.75
Omega-3 Polyunsaturated Fatty Acids and Oxylipins in Neuroinflammation and Management of Alzheimer Disease. Adv Nutr (2016) 0.75
ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease. Trends Endocrinol Metab (2017) 0.75
The CYP19A1 rs3751592 variant confers susceptibility to Alzheimer disease in the Chinese Han population. Medicine (Baltimore) (2016) 0.75
ABCA1 Deficiency Affects Basal Cognitive Deficits and Dendritic Density in Mice. J Alzheimers Dis (2017) 0.75
Role of endolysosomes and cholesterol in the pathogenesis of Alzheimer's disease: Insights into why statins might not provide clinical benefit. Austin J Pharmacol Ther (2014) 0.75
Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease? Transl Neurodegener (2016) 0.75
Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice. PLoS One (2017) 0.75
A novel CCM2 variant in a family with non-progressive cognitive complaints and cerebral microbleeds. Am J Med Genet B Neuropsychiatr Genet (2016) 0.75
Idolizing the clearance of Amyloid-β by microglia. Ann Transl Med (2016) 0.75
Plasma Tau Levels in Cognitively Normal Middle-Aged and Older Adults. Front Aging Neurosci (2017) 0.75
Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. Alzheimers Res Ther (2017) 0.75
Impaired hypoxic tolerance in APP23 mice: a dysregulation of neuroprotective globin levels. FEBS Lett (2017) 0.75
Integrated approach reveals diet, APOE genotype and sex affect immune response in APP mice. Biochim Biophys Acta (2017) 0.75
Transcriptional regulation of APP by apoE: To boldly go where no isoform has gone before: ApoE, APP transcription and AD: Hypothesised mechanisms and existing knowledge gaps. Bioessays (2017) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science (1988) 13.54
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science (2012) 10.42
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med (2012) 8.04
Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science (2010) 8.04
Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem (1997) 7.62
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature (2009) 6.99
Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet (2000) 6.61
Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci (2006) 6.52
Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis (1988) 6.01
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A (2003) 5.44
LRP: a multifunctional scavenger and signaling receptor. J Clin Invest (2001) 5.31
Alzheimer mechanisms and therapeutic strategies. Cell (2012) 5.24
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med (2006) 5.09
Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest (2000) 5.07
Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med (2000) 4.99
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 4.86
2013 Alzheimer's disease facts and figures. Alzheimers Dement (2013) 4.75
ApoE promotes the proteolytic degradation of Abeta. Neuron (2008) 4.75
Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res (1991) 4.31
LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron (2004) 4.29
Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature (1994) 4.28
ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron (2004) 4.21
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol (2013) 4.16
Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet (1997) 4.11
Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron (2003) 4.11
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci (2009) 3.97
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature (2012) 3.80
Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med (1995) 3.54
Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science (1991) 3.42
apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest (2008) 3.36
Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab (2006) 3.35
Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc Natl Acad Sci U S A (1989) 3.26
Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell (2013) 3.24
Alzheimer disease as a vascular disorder: nosological evidence. Stroke (2002) 3.17
Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry (1978) 3.11
Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature (1977) 3.04
Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem (1987) 3.04
Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem (1981) 3.02
Microglia: scapegoat, saboteur, or something else? Science (2013) 2.94
Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta (1987) 2.90
Apolipoprotein E structure: insights into function. Trends Biochem Sci (2006) 2.86
Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol (2009) 2.83
Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med (2012) 2.77
The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature (1989) 2.75
Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med (2004) 2.72
Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem (1994) 2.66
Human apolipoprotein E. The complete amino acid sequence. J Biol Chem (1982) 2.64
A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci (2003) 2.63
Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry (1981) 2.61
Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc Natl Acad Sci U S A (1985) 2.59
Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron (2007) 2.55
Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem (1990) 2.42
Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res (2008) 2.28
Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest (1999) 2.21
Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci (2009) 2.20
Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci (2005) 2.17
Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci U S A (2009) 2.14
Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. J Biol Chem (1979) 2.08
Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem (1994) 2.04
Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron (2009) 2.03
Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci (2006) 2.01
Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest (2008) 2.01
Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem (1993) 1.92
Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem (2005) 1.91
Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A (2013) 1.88
Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet (1994) 1.85
Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. Proc Natl Acad Sci U S A (1992) 1.85
Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol (2003) 1.84
Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem J (2000) 1.84
SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol (2008) 1.83
Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem Biophys Res Commun (1993) 1.80
Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci (2009) 1.79
Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. J Clin Invest (1981) 1.79
Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem J (1995) 1.72
Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem (1997) 1.67
The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci (2007) 1.66
The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem (2005) 1.63
Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol (2003) 1.56
Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry (1996) 1.55
Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J Biol Chem (2006) 1.53
Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J Neurosci (2011) 1.53
Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol (2002) 1.51
ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc Natl Acad Sci U S A (2013) 1.50
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol (2004) 1.50
Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc Natl Acad Sci U S A (2011) 1.50
Apolipoprotein E induces antiinflammatory phenotype in macrophages. Arterioscler Thromb Vasc Biol (2011) 1.47
Proteolytic degradation of amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.46
Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem (1998) 1.45
Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J Biol Chem (1996) 1.45
Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer's disease. Neuron (2014) 0.97
Modulation of mitochondrial complex I activity averts cognitive decline in multiple animal models of familial Alzheimer's Disease. EBioMedicine (2015) 0.85
Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer's disease. Sci Transl Med (2016) 0.81